The neuropathological changes of AD are reflected in its biochemical profile in both fluid and neuroimaging biomarkers, characterized by reduced amyloid-beta (Aβ) levels and elevated concentrations of total and phosphorylated tau protein (3). This evidence concerns the gene MAPT and Alzheimer disease.